Mitesh Borad, Co-Leader, Novel Therapeutics and Therapeutic Modalities Program and Director – Cancer Cell, Gene and Virus (CGV) Therapy Lab, Liver and Biliary Cancer Research Program at Mayo Clinic, shared a post on LinkedIn:
“It was a pleasure joining in on this tour de force by Pedro Uson, MD. By far the most comprehensive assessment of clinical trials in biliary tract cancers – 23,024 patients in 427 trials. What have we learned in the last 45 years?
Immunotherapy is now well established as a foundation, enrollment is being driven by Asia and precision medicine has higher success (which should come as no surprise).”
Title: Landscape of clinical trials and impact of precision medicine in biliary tract cancers in the last 45 years: a systematic review and meta-analysis of biomarker-driven trials
Authors: Pedro Luiz Serrano Uson Junior, Fernando Moura, Frederico Monfardini, Uelson Donizeti Rocioli Junior, Gustavo Prado dos-Santos, Luiz Vicente Rizzo, Edna Terezinha Rother, Maria Fernanda Teixeira, Francisco Tustumi, Daniel Ahn, Mohamad Bassam Sonbol, Juan W. Valle, Jesus M. Banales, Raphael L. C. Araujo, Milind Javle, Tanios Bekaii-Saab, Mitesh J. Borad.
Other articles featuring Mitesh Borad on OncoDaily.